NeuroPace (NPCE) Expected to Announce Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) will likely be issuing its quarterly earnings data after the market closes on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $21.14 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

NeuroPace Stock Performance

NPCE opened at $13.52 on Tuesday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The business has a fifty day simple moving average of $12.53 and a 200 day simple moving average of $9.50. NeuroPace has a 1 year low of $5.45 and a 1 year high of $17.37. The company has a market capitalization of $403.57 million, a PE ratio of -13.52 and a beta of 2.05.

Insider Buying and Selling

In related news, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the transaction, the insider now directly owns 87,062 shares in the company, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,274,145 shares of company stock valued at $49,595,475 over the last ninety days. 22.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Wells Fargo & Company upped their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. Finally, UBS Group began coverage on NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.